Aspiriant LLC’s Leidos LDOS Stock Holding History

Aspiriant LLC’s Portfolio LDOS Stock Details LDOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-135,380	Closed	-$14.6M	–	285
2022 Q1	$14.6M	Sell	135,380 -20	-0%	-$1.93K	0.8%	20
2021 Q4	$12M	Buy	+135,400	New	+$12.7M	0.64%	25

Other funds holding LDOS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Aspiriant LLC's LDOS Position: Q2 2022 in Review

Aspiriant LLC sold out of Leidos (LDOS) in Q2 2022, closing a stake of 135,380 shares — an estimated $14.6M sold.

Aspiriant LLC first reported a position in LDOS in Q4 2021 and held it in 2 quarters. The position peaked at $14.6M in Q1 2022. 528 funds tracked by Wall St. Rank hold LDOS as of Q2 2022.

Aspiriant LLC reported no remaining Leidos position as of Q2 2022 after selling out during the quarter.
Aspiriant LLC sold 135,380 Leidos shares in Q2 2022, an estimated $14.6M.
Aspiriant LLC first reported a position in Leidos in Q4 2021 and held it in 2 quarters.
Aspiriant LLC's Leidos position peaked at $14.6M in Q1 2022.
528 funds tracked by Wall St. Rank held Leidos as of Q2 2022.

Based on Aspiriant LLC's 13F filing for Q2 2022, filed 25 Jul 2022.